# Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

> **NCT03742193** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Osteosarcoma
- Pulmonary Metastases
- Apatinib

## Interventions

- **DRUG:** Apatinib
- **DRUG:** GD regimen

## Key facts

- **NCT ID:** NCT03742193
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-11
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742193, "Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03742193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*